Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Riximyo“
Suchtreffer
Begriffe & Kennungen
Riximyo · 4.8 · Adverse reactions are listed in Table 4. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to <
Eintrag öffnenRiximyo · 4.8 · Adverse reactions were considered as adverse events that occurred at an incidence of ≥ 10%. These included: in
Eintrag öffnenRiximyo · 4.8 · Bulky disease There was a higher incidence of grade 3/4 adverse reactions in patients with bulky disease than
Eintrag öffnenRiximyo · 4.8 · Cardiac disorders Tachycardia Gastrointestinal disorders Abdominal pain upper Skin and subcutaneous Alopecia P
Eintrag öffnenRiximyo · 4.8 · Cardiovascular adverse reactions Cardiovascular reactions during clinical trials with rituximab monotherapy we
Eintrag öffnenRiximyo · 4.8 · Cardiovascular adverse reactions In GPA/MPA Study 1, cardiac events occurred at a rate of approximately 273 pe
Eintrag öffnenRiximyo · 4.8 · Cardiovascular adverse reactions Serious cardiac reactions were reported at a rate of 1.3 per 100 patient year
Eintrag öffnenRiximyo · 4.8 · Cases of posterior reversible encephalopathy syndrome (PRES) / reversible posterior leukoencephalopathy syndro
Eintrag öffnenRiximyo · 4.8 · Cases of progressive multifocal leukoencephalopathy with fatal outcome have been reported following use of rit
Eintrag öffnenRiximyo · 4.8 · Description of selected adverse reactions
Eintrag öffnenRiximyo · 4.8 · During the overall study period, the safety profile of rituximab was consistent with that reported during the
Eintrag öffnenRiximyo · 4.8 · Elderly (65 years and above) The incidence of adverse reactions of all grades and grade 3 /4 adverse reactions
Eintrag öffnenRiximyo · 4.8 · Elderly (65 years and above) The incidence of grade 3/4 blood and lymphatic adverse events was higher in elder
Eintrag öffnenRiximyo · 4.8 · Experience from granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
Eintrag öffnenRiximyo · 4.8 · Experience from non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia (CLL) in adults
Eintrag öffnenRiximyo · 4.8 · Experience from paediatric DLBCL/BL/BAL/BLL
Eintrag öffnenRiximyo · 4.8 · Experience from pemphigus vulgaris The overall safety profile of rituximab in pemphigus vulgaris is based on d
Eintrag öffnenRiximyo · 4.8 · Experience from rheumatoid arthritis
Eintrag öffnenRiximyo · 4.8 · Gastrointestinal disorders Gastrointestinal perforation in some cases leading to death has been observed in pa
Eintrag öffnenRiximyo · 4.8 · Haematologic adverse reactions In clinical trials with rituximab monotherapy given for 4 weeks, haematological
Eintrag öffnen